Lilly Places Additional Marketing Support Behind Cymbalta For Diabetic Pain

Lilly is ramping up initiatives behind its selective serotonin and norepinephrine reuptake inhibitor Cymbalta (duloxetine) for the diabetic pain market

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet